Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Jupiter Neurosciences announced a definitive license agreement to acquire perpetual exclusive U.S. rights to ALA-002, a patented non-racemic MDMA formulation with FDA Novel Chemical Entity designation, for up to $100 million in milestones and royalties. This acquisition diversifies Jupiter's clinical-stage CNS asset portfolio by adding a novel psyc…